Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based Enzymotec has started a clinical trial to assess the efficacy of Vayarin in adults with attention deficit hyperactivity disorder (ADHD).
Subscribe to our email newsletter
The Israeli firm is a developer, manufacturer and marketer of new bio-active lipid based nutritional ingredients and medical foods.
Around 171 patients between the ages of 18 and 55 will be enrolled in the multi-center, randomized, double-blind, placebo-controlled trial to be carried out in the US, including the NYU School of Medicine.
Enzymotec division VAYA Pharma CEO Robert Crim said: "The high risk of abuse is a critical factor when trying to manage ADHD in the adult population. The fact that Vayarin is considered safe, with no addictive side effects, represents a tremendous advantage in the management of ADHD."
The trial will evaluate the efficacy of Vayarin in adults with ADHD, measured primarily by the ADHD Investigator Symptom Rating Scale (AISRS).
According to Enzymotec head of VAYA Pharma Research Center Dr Yael Richter, Vayarin has been clinically shown to be safe and effective for the management of ADHD in children.
Richter added: "Vayarin is a unique lipid composition specifically designed to manage certain lipid imbalances associated with this lifelong neurodevelopmental disorder that tends to persist into adulthood. Approximately 60% of children with ADHD carry the disorder into adulthood.
"This translates into approximately 4 percent of the adult population, or 8 million adults in the United States, which creates a large opportunity for Enzymotec."